Clinical Trial Update: A Dose-Ranging, Cross-over Study of the Safety and Efficacy of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD) [Phase 2]

View source ↗

Summary

A Phase 2 dose-ranging, cross-over study evaluated the safety and efficacy of ABT-089 in adults with ADHD. The trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• ABT-089

Snippet

Sponsor: Abbott | Conditions: Attention-Deficit/Hyperactivity Disorder | Phase 2 | Status: COMPLETED